Publications des scientifiques de l'IRD

Ameen S. M., Rolain J. M., Le Poullain M. N., Roux V., Raoult Didier, Drancourt M. (2014). Serum concentration of co-trimoxazole during a high-dosage regimen. Journal of Antimicrobial Chemotherapy, 69 (3), p. 757-760. ISSN 0305-7453.

Titre du document
Serum concentration of co-trimoxazole during a high-dosage regimen
Année de publication
2014
Type de document
Article référencé dans le Web of Science WOS:000331827200027
Auteurs
Ameen S. M., Rolain J. M., Le Poullain M. N., Roux V., Raoult Didier, Drancourt M.
Source
Journal of Antimicrobial Chemotherapy, 2014, 69 (3), p. 757-760 ISSN 0305-7453
Objectives: Sulfamethoxazole and trimethoprim have been used for decades, yet high dosages are rarely reported. We aimed to measure blood concentrations of both molecules in this situation. Methods: Between 2002 and 2010, 22 patients received two tablets of co-trimoxazole three times a day, equivalent to a daily dosage of 2400 mg of sulfamethoxazole and 480 mg of trimethoprim. The trimethoprim and sulfamethoxazole concentrations were determined 3 h after administration using ion-paired HPLC. Results: In the presence of a negative control, which yielded no peaks at the retention times for trimethoprim and sulfamethoxazole, the mean +/- SD value for sulfamethoxazole concentration was 161.01 +/- 69.154 mg/L and the mean +/- SD value for trimethoprim was 5.788 +/- 2.74 mg/L. Conclusions: These concentrations are largely above the trimethoprim and sulfamethoxazole MIC distributions as well as the trimethoprim resistance clinical breakpoint (4 mg/L) reported by EUCAST in 2012 for most bacterial pathogens, including Gram-positive species such as Staphylococcus aureus. Our results support proposing a high-dosage regimen of co-trimoxazole as a suitable alternative for methicillin-resistant S. aureus infections.
Plan de classement
Santé : généralités [050]
Identifiant IRD
PAR00011502
Contact